CEO Jack Y. Zhang Buys 180,504 Restricted Shares in Bet on Amphastar’s Future Amid Stock Decline

Amphastar’s Insider Activity: A Snapshot of Confidence Amid Volatility

Amphastar Pharmaceuticals Inc. has just recorded a significant insider transaction: CEO and Chief Scientific Officer Jack Y. Zhang purchased 180,504 shares of the company’s common stock on March 9, 2026. The transaction was made at a price of $0.00 because the shares were restricted stock units (RSUs) that vest in equal annual installments beginning March 9, 2027. The purchase increased Zhang’s post‑transaction holdings to 3,014,621 shares, representing roughly 1.7 % of the outstanding shares. This move comes at a time when the stock has been in a steep decline – down 34 % month‑to‑date and 28 % year‑to‑date – and follows a string of sales by Zhang in early March, where he off‑loaded 7,773 shares at $19.34 and another 3,077 shares at the same price.

What Investors Should Take Away The purchase of RSUs, rather than market‑price shares, signals a long‑term commitment: Zhang is betting that the company’s share price will recover and rise over the next four years. For investors, this can be viewed as a bullish sign that management sees intrinsic value that the market has yet to recognize. However, the timing—right after a series of sales—raises questions about whether the purchases were pre‑planned or a response to a perceived undervaluation. The fact that the RSUs have not yet vested means the market cannot yet test the strength of this conviction, so the impact on price will likely be muted in the short term.

Zhang Jack Y.: A Profile of Cautious Optimism Zhang’s historical transaction pattern shows a blend of short‑term selling and long‑term holding. In March 2026 alone, he sold 11,850 shares at around $19.34 and $19.96, totaling a net cash inflow of roughly $229,000. Yet, his holdings remain large, with 6,827,679 shares recorded as a holding in the filings. The recent RSU purchase and the earlier sale of 180,504 shares at a nominal price reflect a strategy of balancing liquidity needs with a belief in the company’s future upside. His role as both CEO and Chief Scientific Officer suggests he is closely involved in product development pipelines; thus, his confidence likely stems from a belief that upcoming generic or proprietary launches will lift the company’s earnings profile, justifying the long‑term stake.

Market Context and Forward Outlook Amphastar’s market cap sits at $888 million, with a price‑to‑earnings ratio of 9.8, comfortably below the broader Nasdaq average, indicating a potential valuation discount. The stock’s 52‑week high of $31.26 and recent low of $18.52 highlight a volatile, but still potentially attractive, trading range. Investor sentiment remains neutral (0 on the social‑media scale) and buzz is average, suggesting that the market has not yet reacted strongly to insider activity.

Going forward, investors should monitor whether the RSU vesting triggers further buying activity from the CEO, and watch for any corporate announcements that could justify a rebound. If the company delivers on its drug development pipeline and improves earnings, Zhang’s long‑term stake could translate into significant upside, reinforcing confidence in the management team’s vision.